Compare TANH & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TANH | AEMD |
|---|---|---|
| Founded | 2001 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.3M |
| IPO Year | 2013 | 2008 |
| Metric | TANH | AEMD |
|---|---|---|
| Price | $12.84 | $5.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 34.8K | ★ 2.3M |
| Earning Date | 05-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.53 |
| 52 Week High | $29.89 | $29.45 |
| Indicator | TANH | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 51.59 |
| Support Level | $12.62 | $3.20 |
| Resistance Level | $17.98 | $6.69 |
| Average True Range (ATR) | 2.22 | 0.33 |
| MACD | -0.66 | -0.25 |
| Stochastic Oscillator | 3.15 | 22.45 |
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks. The company has two reportable segments: the Consumer Product segment, and the Electric Vehicle (EV) segment.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.